Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Debt-free cannabis company set for next stage of growth

The following is a transcription of the above video, and The Market Online has edited it for clarity . Nextleaf Solutions (CSE:OILS) , is a debt-free cannabis processor known for its multi patented, scalable extraction technology. The company offers a diverse portfo...

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. In an Aug. 20 research note, analyst Ed Arce reported that H.C. Wainwright & Co. raised its target price on Nabriva Therapeutics Plc (NBRV:NASDAQ) to $8 per sh...

The Dales Report panelists agree on this vote: Way to go, Ohio

Welcome to the Trade To Black podcast on Stockhouse.com . In the episode in the above video, Shadd Dales, Anthony Varrell and Benjamin Smith talk in-depth about the following stories and more: Ohio voters approve the legalization of adult use cannabis ...

Buzz on the Bullboards: Summer's most talked about stocks

August has been a rough month for North American stock markets, with red days and a lot of flat trading activity. Shares of U.S. banks fell this week after several regional lenders were hit with a credit downgrade. Retailers are stuck with products that aren&CloseCurl...

One-Hour Delivery Service Holds Potential to Disrupt Industry

Kelly Abbott, CEO of ParcelPal Technology, sits down with Anthony Varrell of StoneBridge Partners to discuss his company's disruptive technology and expansion plans into the United States. For those who are not familiar with ParcelPal Technology Inc.'s (PKG:CSE) story...

Mexican gold junior I really like

Editor’s note: The Pediment Gold story was first reported by Ticker Trax’s Thom Calandra in an article posted her e . I first wrote about Pediment Gold Corp ( TSX: T.PEZ , Stock Forum ) in a private report delivered on June 18, 2007....

Growing Rapidly and Efficiently in California's Cannabis Market

This podcast is part of our Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public marketplace. Stockhouse Media's Omri Wallach was recently joined live by Arni ...

PODCAST: How this Cannabis Co. is Creating a Self-Contained Ecosystem

This podcast is part of our Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public marketplace. Stockhouse Media's Dave Jackson was recently joined live by Arni ...

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study

Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. This...
1 2 3 4 5 6 7 8 9 10 ...